Med. praxi. 2017;14(4):173-176 | DOI: 10.36290/med.2017.032

What are the benefits of the combination of perindopril and amlodipine in treating hypertension?

MUDr. Jan Pyszko, doc. MUDr. Jan Václavík, Ph.D., FESC
I. interní klinika – kardiologická, Fakultní nemocnice Olomouc a Lékařská fakulta Univerzity Palackého v Olomouci

The treatment of arterial hypertension is not only aimed at maintaining blood pressure below target levels. Modern therapy shouldalso be well tolerated, have simple dosage in order to achieve good patient adherence, and, in particular, positively influencecardiovascular morbidity and mortality of patients. The treatment based on perindopril has the largest evidence base and, in thefixed combination with amlodipine, represents the drug of choice in many clinical settings.

Keywords: arterial hypertension, treatment, combinations, perindopril, amlodipine, target organ damage

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pyszko J, Václavík J. What are the benefits of the combination of perindopril and amlodipine in treating hypertension? Med. praxi. 2017;14(4):173-176. doi: 10.36290/med.2017.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J jr., Widimský J, et al. Hypertenze. Praha, Triton 2014.
    2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal 2013: 2159-2219. Go to original source... Go to PubMed...
    3. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11.000 participants from 42 trials. Am J Med, 2009; 122: 290-300. Go to original source... Go to PubMed...
    4. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 2006; 113(9): 1213-1225. Go to original source... Go to PubMed...
    5. Hatalová K, Hatala R, Pella D, Šidlo R. SYMBIO - study of optimized blood pressure lowering terapy with fixed combination of perindopril arginine/amlodipine. Interná med. 2012; 12(2).
    6. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    7. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment stratégy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. JAMA 2003; 290: 2805-2816. Go to original source... Go to PubMed...
    8. Redfield MM, Jacobsen SJ, Burnett JC jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic a diastolic ventricular dysfunction in the community: appreciating the scope of heart failure epidemic. JAMA 2003; 289: 194-202. Go to original source... Go to PubMed...
    9. Mazza A, Schiavon L, Zuin M, Lenti S, Ramazzina E, Rubello D, Casaglia E. Effects of the Antihypertensive Fixed-Dose Combinations on an Early Marker of Hypertensive Cardiac Damage in Subjects at Low Cardiovascular Risk. American Journal of Hypertension, 2016; 29(8): 969-975. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.